HOOK - HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting | Benzinga
- Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ?20
- Conference call on Tuesday, June 4, at 4:15 p.m. ET
NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, HOOKIPA or the Company)), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA's Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET. Complete details and registration information are included below. The call will detail the Company's Phase 2 clinical data of HB-200 in combination with pembrolizumab for the treatment of human papillomavirus 16 positive head and neck cancer, including preliminary progression-free survival and overall survival data for patients with CPS ?20.
Call Details:
HOOKIPA HB-200 ASCO Data Update
Tuesday, June 4, 2024, 4:15 p.m. ET
Webcast Registration
Dial-in Registration
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other unnamed indications. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.